BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kennedy RB, Ovsyannikova IG, Palese P, Poland GA. Current Challenges in Vaccinology. Front Immunol. 2020;11:1181. [PMID: 32670279 DOI: 10.3389/fimmu.2020.01181] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 de la Fuente J, Contreras M. Vaccinomics: a future avenue for vaccine development against emerging pathogens. Expert Rev Vaccines 2021;:1-9. [PMID: 34582295 DOI: 10.1080/14760584.2021.1987222] [Reference Citation Analysis]
2 Nicoli F, Mantelli B, Gallerani E, Telatin V, Squarzon L, Masiero S, Gavioli R, Palù G, Barzon L, Caputo A. Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine. NPJ Vaccines 2022;7:37. [PMID: 35292655 DOI: 10.1038/s41541-022-00458-0] [Reference Citation Analysis]
3 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
4 Andrei G. Vaccines and Antivirals: Grand Challenges and Great Opportunities. Front Virol 2021;1:666548. [DOI: 10.3389/fviro.2021.666548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Asfaw M, Senbit M, Yesuf M, Dagnaw M, Birhan G, Abat AS, Ibrahim SM. A Preliminary Investigation on a Commercial Ovine Pasteurellosis Vaccine Using Clinical and Pathological Endpoints. IDR 2022;Volume 15:2937-48. [DOI: 10.2147/idr.s365745] [Reference Citation Analysis]
6 Vahedifard F, Chakravarthy K. Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19. Emergent Mater 2021;:1-25. [PMID: 33615140 DOI: 10.1007/s42247-021-00168-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
7 Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat Rev Drug Discov 2021;20:817-38. [PMID: 34433919 DOI: 10.1038/s41573-021-00283-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Broudic K, Amberg A, Schaefer M, Spirkl HP, Bernard MC, Desert P. Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery. Toxicol Appl Pharmacol 2022;:116143. [PMID: 35843341 DOI: 10.1016/j.taap.2022.116143] [Reference Citation Analysis]
9 Liba Z, Kraus J, Necas T, Necas J, Klugar M, Krsek P. Movement disorders, cerebral palsy and vaccination. Eur J Paediatr Neurol 2022;36:143-50. [PMID: 34979476 DOI: 10.1016/j.ejpn.2021.12.006] [Reference Citation Analysis]
10 Han X, Alu A, Liu H, Shi Y, Wei X, Cai L, Wei Y. Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and stem cell therapy. Bioactive Materials 2022. [DOI: 10.1016/j.bioactmat.2022.01.011] [Reference Citation Analysis]
11 Choi JY, Mahadik B, Fisher JP. 3D printing technologies for in vitro vaccine testing platforms and vaccine delivery systems against infectious diseases. Essays Biochem 2021;65:519-31. [PMID: 34342360 DOI: 10.1042/EBC20200105] [Reference Citation Analysis]
12 Abernathy ME, Dam KA, Esswein SR, Jette CA, Bjorkman PJ. How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Viruses 2021;13:2106. [PMID: 34696536 DOI: 10.3390/v13102106] [Reference Citation Analysis]
13 Constantin C, Pisani A, Bardi G, Neagu M. Nano-carriers of COVID-19 vaccines: the main pillars of efficacy. Nanomedicine (Lond) 2021;16:2377-87. [PMID: 34632802 DOI: 10.2217/nnm-2021-0250] [Reference Citation Analysis]
14 Poland GA, Ovsyannikova IG, Kennedy RB. Pharmacogenomics and Vaccine Development. Clin Pharmacol Ther 2021;110:546-8. [PMID: 34097754 DOI: 10.1002/cpt.2288] [Reference Citation Analysis]
15 Dorigatti E, Schubert B. Graph-theoretical formulation of the generalized epitope-based vaccine design problem. PLoS Comput Biol 2020;16:e1008237. [PMID: 33095790 DOI: 10.1371/journal.pcbi.1008237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Singh A. Why not the 'marker' or DIVA vaccines for the control of emerging infectious diseases of humans? Vaccine 2021;39:1476-7. [PMID: 33573864 DOI: 10.1016/j.vaccine.2021.01.069] [Reference Citation Analysis]
17 Asadi K, Gholami A. Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review. Int J Biol Macromol 2021;182:648-58. [PMID: 33862071 DOI: 10.1016/j.ijbiomac.2021.04.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Ryan M, Montgomery J. Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented. The Lancet Respiratory Medicine 2022;10:624-5. [DOI: 10.1016/s2213-2600(22)00091-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Le T, Sun C, Chang J, Zhang G, Yin X. mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases. Viruses 2022;14:401. [DOI: 10.3390/v14020401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]